Page 185 - MI-2-3

Microbes & Immunity A novel anti-EphB2 monoclonal antibody for flow cytometry

using the REMAP method. Monoclon Antib Immunodiagn doi: 10.3892/ijmm.2023.5221
Immunother. 2021;40(4):191-195.
52. Kaneko MK, Suzuki H, Kato Y. Establishment of a novel
doi: 10.1089/mab.2021.0014 cancer-specific Anti-HER2 monoclonal antibody H(2)
Mab-250/H(2)Casmab-2 for breast cancers. Monoclon Antib
48. Asano T, Kaneko MK, Takei J, Tateyama N, Kato Y. Epitope
mapping of the Anti-CD44 monoclonal antibody (C( ) Immunodiagn Immunother. 2024;43(2):35-43.
44
Mab-46) using the REMAP method. Monoclon Antib doi: 10.1089/mab.2023.0033
Immunodiagn Immunother. 2021;40(4):156-161.
53. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y. A cancer-
doi: 10.1089/mab.2021.0012 specific monoclonal antibody against podocalyxin exerted
antitumor activities in pancreatic cancer xenografts. Int J
49. Okada Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y. Epitope
mapping of an Anti-Mouse CD39 monoclonal antibody Mol Sci. 2023;25(1):161.
using PA scanning and RIEDL scanning. Monoclon Antib doi: 10.3390/ijms25010161
Immunodiagn Immunother. 2024;43(2):44-52.
54. Kato Y, Kaneko MK. A cancer-specific monoclonal antibody
doi: 10.1089/mab.2023.0029 recognizes the aberrantly glycosylated podoplanin. Sci
Rep. 2014;4:5924.
50. Sharkey RM, Govindan SV, Cardillo TM, et al. Selective and
concentrated accretion of SN-38 with a CEACAM5-targeting doi: 10.1038/srep05924
antibody-drug conjugate (ADC), labetuzumab govitecan 55. Hosking M, Shirinbak S, Omilusik K, et al. 268 Development
(IMMU-130). Mol Cancer Ther. 2018;17(1):196-203.
of FT825/ONO-8250: An off-the-shelf CAR-T cell
doi: 10.1158/1535-7163.Mct-17-0442 with preferential HER2 targeting and engineered to
enable multi-antigen targeting, improve trafficking, and
51. Li G, Suzuki H, Ohishi T, et al. Antitumor activities of
a defucosylated antiEpCAM monoclonal antibody in overcome immunosuppression. J Immunother Cancer.
colorectal carcinoma xenograft models. Int J Mol Med. 2023;11(Suppl 1):A307.
2023;51(2):18. doi: 10.1136/jitc-2023-SITC2023.0268

Volume 2 Issue 3 (2025) 177 doi: 10.36922/mi.5728